{
    "Trade/Device Name(s)": [
        "Virtuoso\u2122 System for IHC PR (1E2) using the VENTANA iScan HT"
    ],
    "Submitter Information": "Ventana Medical Systems, Inc.",
    "510(k) Number": "K142965",
    "Predicate Device Reference 510(k) Number(s)": [
        "K111869",
        "K122143"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "OEO"
    ],
    "Summary Letter Date": "July 13, 2015",
    "Summary Letter Received Date": "July 14, 2015",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 864.1860"
    ],
    "Regulation Name(s)": [
        "Immunohistochemistry reagents and kits"
    ],
    "Analyte Class(es)": [
        "anatomic pathology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "Progesterone Receptor (PR) protein"
    ],
    "Specimen Type(s)": [
        "Formalin-fixed, paraffin-embedded tissue"
    ],
    "Specimen Container(s)": [
        "Glass slide"
    ],
    "Instrument(s)/Platform(s)": [
        "VENTANA iScan HT scanner",
        "Computer",
        "Monitor",
        "Keyboard",
        "Mouse",
        "BenchMark XT stainer",
        "BenchMark ULTRA stainer"
    ],
    "Method(s)/Technology(ies)": [
        "Digital slide scanning",
        "Immunohistochemistry",
        "Computer-assisted image analysis"
    ],
    "Methodologies": [
        "Qualitative detection",
        "Image acquisition",
        "Image interpretation"
    ],
    "Submission Type(s)": [
        "System",
        "Accessory",
        "Software",
        "Instrument"
    ],
    "Document Summary": "FDA 510(k) summary for Virtuoso\u2122 System for IHC PR (1E2) using the VENTANA iScan HT for digital slide scanning and qualitative detection of PR protein in breast cancer tissue",
    "Indications for Use Summary": "Intended for in vitro diagnostic use as an aid to the pathologist in the qualitative detection of progesterone receptor (PR) protein in formalin-fixed, paraffin-embedded normal and neoplastic tissue from breast cancer patients for whom endocrine treatment is being considered, in conjunction with CONFIRM\u2122 anti-Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody assay; not the sole basis for treatment",
    "fda_folder": "Hematology"
}